BioSpace News Archive

Centene Corporation announced that it has commenced an underwritten public offering to sell $1,800,000,000 of senior notes.

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results and provide a corporate update.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (IND) application for DCR-AUD, the Company’s investigational RNAi candidate for the treatment of alcohol use disorder (AUD).

Karen Linehan and Philippe Luscan, who have led Legal, Ethics & Business Integrity and Industrial Affairs at Sanofi for the last 14 and 13 years respectively have decided to retire.

Tissue and bone adhesives are crucial additions to normal methods of musculoskeletal tissue repair. Advancements in techniques and growth of organically derived adhesives which are useful in orthopedic surgery drive the global tissue glue and bio-adhesive sealants market.

Infertility is medically described as the inability of a woman to become pregnant after nine months of unprotected sexual intercourse.

Hemorrhagic stroke is also called cerebral hemorrhage. It is a condition caused by the rapture and bleeding of cerebral blood vessels.

Substantial rise in the number of clinical trials intended towards the development of potent and advanced bispecific drugs over the past decade has acted favorably for the global bispecific antibody therapeutics market.

Avian influenza can be defined as the disease caused by infection by the bird flu Type-A virus. These viruses are found commonly in aquatic birds and they can cause infection in domestic poultry and other species of birds.

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, and Kumquat Biosciences announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.